Highlights Newbury Pharmaceuticals AB

Equities

NEWBRY

SE0015244884

Delayed Nasdaq Stockholm Other stock markets 08:24:27 2024-06-27 EDT			5-day change	1st Jan Change
3.32 ^SEK	-2.35%		-4.05%	+8.14%

06-20	Newbury Pharmaceuticals Secures Generic Approval for Liraglutide Pre-Filled Pen	CI
04-10	Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Newbury Pharmaceuticals Secures Generic Approval for Liraglutide Pre-Filled Pen	06-20	CI
Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	04-10	CI
Newbury Pharmaceuticals Secures SEK9 Million Sales Order	02-22	MT
Newbury Pharmaceuticals Receives International Sales Order Valued At 8.8 Million	02-22	CI
Newbury Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended November 30, 2023	01-10	CI
Newbury Pharmaceuticals AB Reports Earnings Results for the Full Year Ended August 31, 2023	23-10-11	CI
Newbury Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter Ended August 31, 2023	23-10-11	CI
Newbury, Amarox Sign Distribution Deal for Sweden, Denmark	23-10-06	MT
Newbury Signs Contract with Amarox Limited to Represent and Distribute Their Products in Sweden and Denmark	23-10-06	CI
Newbury Pharmaceuticals Strengthens its Portfolio with Levodopa/Benserazide	23-09-22	CI
Newbury Secures Access to Hospital Product Portfolio in New Partnership	23-08-23	MT
Newbury Pharmaceuticals AB Gains Access to the Nordic Hospital Market with A New Strategic Partnership for Prescription Medicine	23-08-23	CI
Newbury Pharmaceuticals Gets OK to Sell Peptide Product in Sweden	23-07-19	MT
Newbury Pharmaceuticals Announces the Marketing Authorization of Desmopressin Newbury 60, 120 & 240 Mg Sublingual Tablets in Sweden	23-07-19	CI
Newbury Pharmaceuticals AB Provides Earnings Guidance for the Year 2028	23-06-16	CI
Newbury Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	23-06-14	CI
Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	23-04-12	CI
Newbury Pharmaceuticals Announces the Marketing Authorization of Lapatinib Newbury 250 Mg Film-Coated Tablets in Sweden	23-03-24	CI
Newbury Pharmaceuticals Announces the Marketing Authorization of Dimethyl Fumarate Newbury 120 & 240 Mg Hard Capsule in Sweden	23-03-06	CI
Newbury Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended November 30, 2022	23-01-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Newbury Pharmaceuticals AB

Equities

NEWBRY

SE0015244884

Highlights

Filters